Market News & Trends
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase 2b/3 Data
Anavex Life Sciences Corp. recently announced the The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase 2b/3 study…
Abzena Strengthens Board With Appointment of Biopharma Industry Leader, Dr. Moncef Slaoui
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef Slaoui, PhD, to its Board…
Iconovo & Lonza to Collaborate on the Formulation Development of an Intranasal Biologic
Iconovo AB, a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced that Iconovo and Lonza initiated…
Alcami Announces CEO Transition
[caption id="attachment_144551" align="alignleft" width="153"] Patrick Walsh[/caption] Alcami Corporation, a leading contract development and manufacturing organization (CDMO), recently announced the resignation of Bill Humphries. Alcami’s Board…
Vetter Introduces the Next Evolution of the V-OVS Syringe Closure System
Vetter recently announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system. The new closure, V-OVS next, will further…
Micron Biomedical Wins $2 Million BARDA Competition for its Collaboration With Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles
Micron Biomedical recently announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare…
BioMed X Institute Launches New Collaboration With Daiichi Sankyo in Cancer Therapy
BioMed X recently announced the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the…
PulseSight Therapeutics Announces Initiation of Clinical Plan of Transferrin Vectorized Therapy for Dry AMD/Geographic Atrophy
PulseSight Therapeutics SAS recently announced it has submitted a Clinical Trial Authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé…
Pheno Therapeutics Granted Clinical Trial Authorization for Lead Multiple Sclerosis Therapeutic Candidate
Pheno Therapeutics Limited recently announced it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead…
Kindeva Drug Delivery & Emervax Partner to Bring Game Changing Vaccine Administration to Patients
Kindeva Drug Delivery and Emervax recently announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva…
Sling Therapeutics Announces Positive Topline Results From Phase 2b/3 Trial of Oral Small Molecule Linsitinib in Patients With Thyroid Eye Disease
Sling Therapeutics, Inc. recently announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe…
Invivyd Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variant XEC
Invivyd, Inc. recently announced new in vitro neutralization data show continued neutralizing activity of PEMGARDA (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC.…
BioDuro Opens New Solid-Phase Peptide Synthesis Scale-Up Facility
BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory at its Shanghai…
Windward Bio Launches With $200-Million Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma & COPD
Windward Bio recently announced its official launch. OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200M with the co-investment…
Menarini Group & Insilico Medicine Enter Second Exclusive Global License Agreement
The Menarini Group, Stemline Therapeutics, Inc., and Insilico Medicine recently announced the companies have entered into an exclusive licensing agreement granting Stemline the global rights…
Genenta Strengthens Agreement With AGC Biologics to Boost Cell Therapy Manufacturing
Genenta Science recently announced it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and…
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments From Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) recently announced Boehringer Ingelheim has exercised an option for rights to a fourth novel oncology target from an ongoing discovery collaboration. The…
Rigel Announces R289 Granted Orphan Drug Designation for MDS
Rigel Pharmaceuticals, Inc. recently announced the US FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R289, Rigel’s potent…
Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along with the results of a…
RheumaGen Launches With $15-Million Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
RheumaGen, Inc. recently announced the close of a $15-million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The financing will support…
